In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals, with a price target of $10.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Andres Y. Maldonado’s rating is based on Zentalis Pharmaceuticals’ strategic advancements and promising clinical developments. The company is focused on its Cyclin E1+ strategy, particularly with azenosertib, which is being tested in pivotal trials for platinum-resistant ovarian cancer, a condition with significant unmet medical needs. The potential for accelerated approval of azenosertib in this indication represents a near-term value driver for the company.
Moreover, Zentalis is expanding its research into other tumor types by exploring combinations of azenosertib with other therapies, such as T-DXd, in HER2-expressing tumors. This expansion into new solid tumor opportunities demonstrates Zentalis’ commitment to broadening the reach of its therapies. The company’s methodical approach and evidence-based platform reinforce the Buy rating, as these efforts are expected to enhance the therapeutic impact and commercial potential of their lead asset.